Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
blincyto | Biologic Licensing Application | 2025-04-29 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
lymphoid leukemia | — | D007945 | C91 |
Expiration | Code | ||
---|---|---|---|
blinatumomab, Blincyto, Amgen Inc. | |||
2025-03-29 | Orphan excl. |
Code | Description |
---|---|
J9039 | Injection, blinatumomab, 1 microgram |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 9 | 18 | 6 | 1 | 2 | 30 |
Lymphoid leukemia | D007945 | — | C91 | 9 | 17 | 5 | 1 | 2 | 28 |
Leukemia | D007938 | — | C95 | 7 | 17 | 6 | 1 | 2 | 27 |
Residual neoplasm | D018365 | — | — | 1 | 4 | — | 1 | — | 6 |
Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | — | — | 2 | 1 | — | 1 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 4 | 7 | 2 | — | — | 10 |
B-cell lymphoma | D016393 | — | — | 3 | 4 | 1 | — | — | 6 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 3 | 1 | — | — | 4 |
Recurrence | D012008 | — | — | — | — | 1 | — | 1 | 2 |
Hodgkin disease | D006689 | — | C81 | 1 | 2 | 1 | — | — | 2 |
Aggression | D000374 | EFO_0003015 | — | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 2 | 5 | — | — | — | 6 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | 2 | — | — | — | 4 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 2 | — | — | — | 2 |
Philadelphia chromosome | D010677 | — | — | — | 2 | — | — | — | 2 |
Biphenotypic leukemia acute | D015456 | — | C95.0 | 1 | 2 | — | — | — | 2 |
T-cell leukemia | D015458 | — | — | — | 1 | — | — | — | 1 |
Reactive arthritis | D016918 | EFO_0007460 | M02.3 | — | 1 | — | — | — | 1 |
Myeloid leukemia chronic-phase | D015466 | — | — | — | 1 | — | — | — | 1 |
Myeloid leukemia | D007951 | — | C92 | — | 1 | — | — | — | 1 |
Myeloid leukemia accelerated phase | D015465 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Blinatumomab |
INN | blinatumomab |
Description | Blinatumumab (human BiTE) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1742992 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB09052 |
UNII ID | 4FR53SIF3A (ChemIDplus, GSRS) |